Daraxonrasib

EN Texto en inglés Aún no hay artículo en tu idioma: extracto en inglés.

Daraxonrasib, sold under the brand name Rasonque, is an anti-cancer medication used for the treatment of pancreatic cancer. It is an inhibitor of the RAS GTPase family. It is an orally administered small molecule pan-RAS inhibitor. It was developed by Revolution Medicines. It inhibits all three key members of the Ras superfamily: KRAS, HRAS, and NRAS. The three RAS proteins are GTPases that become active when bound to GTP but normally convert this GTP to GDP and thereby become inactive. RAS proteins that are bound to GDP and GTP are termed respectively RAS(OFF) and RAS(ON). Daraxonrasib targets RAS in the ON state, but not in the OFF state. Daraxonrasib was approved for medical use in the United States in August 2026.